Developer docs
API playgroundTry for free, no card

Search company profiles

Pardini Group

Full company profile

uuid000tn87

Namestring
Pardini Group
Legal namestring
Grupo Hermes Pardini
Company typeenum
Public
Founded yearint
1959
Descriptiontext

Pardini Group (legal name Grupo Hermes Pardini, public ticker PARDINI on B3 Novo Mercado) is a Brazilian diagnostic medicine company founded in 1959 by Dr. Hermes Pardini in Belo Horizonte, Minas Gerais, now headquartered in Vespasiano. The group operates an integrated diagnostic platform combining 125 owned service units, approximately 6,000 partner laboratories served via the Lab-to-Lab B2B channel, and coverage reaching 1,930-2,000+ Brazilian municipalities. It offers more than 8,000 test types spanning clinical analysis, diagnostic imaging, vaccination, cryopreservation, human and veterinary genetics, toxicology, oncology genomics, and personalized medicine, organized across 14 brands including Hermes Pardini (flagship), Padrão, Diagnostika, Progenetica, CMNG, Ecoar, Humberto Abrão, Labfar, DLE, Biocod, Toxicologia Pardini, Solução, My Pardini, and Telemedicina Pardini.

The underlying technology stack is anchored by the Vespasiano-based Núcleo Técnico Operacional (NTO), described as the world's largest specialized laboratory production hub by installed capacity and capable of processing more than 5 million tests per month via parallel automated and semi-automated lines. The 2020-launched Enterprise platform extends this to seven interconnected production nuclei (central nucleus near Belo Horizonte International Airport plus six advanced nuclei) with combined capacity for 160 million tests annually, real-time command center monitoring, and a Just-in-Time reagent model replacing direct procurement. Advanced diagnostic modalities include Next-Generation Sequencing with CNV analysis for hereditary cancer panels and HRD/HRR panels, LC-MS/MS mass spectrometry enabling newborn screening for over 300 treatable diseases, PD-L1 immunohistochemistry on VENTANA BenchMark ULTRA, and the Guardian automated molecular biology platform operating Brazil's largest COVID-19 RT-PCR testing center at 20,000 tests per day. R$200 million+ has been invested in technology infrastructure.

The business model operates four parallel revenue streams: (1) direct patient services at owned units billed primarily through health insurance operators on a transactional fee basis, (2) Lab-to-Lab B2B professional services and specialized testing to approximately 6,000 partner laboratories, (3) enterprise billing to health insurance operators and self-management plans via a dedicated commercial team, and (4) specialized professional services in toxicology (10,000+ corporate clients) and personalized medicine (600+ physicians, 3 million+ tests performed last year). The Pardini family retains 64.7% ownership post-IPO; the company has executed more than 12 acquisitions between 2012-2019 to build geographic and specialty breadth, and pursues an explicit strategy of democratizing access to advanced diagnostics across urban and rural Brazil through the Enterprise logistics network.

Short descriptiontext

Grupo Pardini is a publicly listed Brazilian diagnostic medicine company serving patients, 6,000+ partner laboratories, health insurers, and 10,000+ corporate clients across 1,930+ municipalities through 125 owned units and an integrated platform spanning clinical analysis, genomics, imaging, and toxicology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersVespasiano, Brazil
HQ citystring
Vespasiano
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical diagnostic services, medical laboratory testing, personalized genetic medicine, diagnostic imaging services, occupational toxicology testing
Industry1 code
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Diagnostic Medicine and Clinical Laboratory Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Laboratory Diagnostic Services
TypeTransaction Fee
Description

Clinical analysis, diagnostic imaging, vaccination, cryopreservation, and genetic testing services provided to patients at owned units and through health insurance billing.

2Laboratory Support Services (Lab-to-Lab)
TypeProfessional Services
Description

B2B services provided to approximately 6,000 partner laboratories across Brazil, including specialized testing, assessments, and operational support.

3Health Insurance Operator Services
TypeTransaction Fee
Description

Services billed through health insurance operators, self-management companies, and health insurance providers.

4Specialized Testing Services
TypeProfessional Services
Description

Toxicology testing, personalized medicine, genetic testing, and other specialized diagnostic services.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Grupo Pardini is a Brazilian diagnostic medicine group that provides clinical analysis, diagnostic imaging, vaccination, cryopreservation, genetic and genomic testing, toxicology, and personalized medicine services through 125 owned service units and a lab-to-lab B2B support network reaching approximately 6,000 partner laboratories across 1,930 municipalities. The group operates one of the largest automated laboratory production hubs in the world, capable of processing more than 5 million tests per month and up to 160 million tests per year through its Enterprise integrated model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 160 million tests per year capacity across seven production nuclei
+5 more records
Product overview1 text field

Pardini Group is a Brazilian diagnostic medicine company organized as a multi-brand portfolio spanning clinical analysis, diagnostic imaging, genetics, toxicology, telemedicine, and personalized medicine. The core platform is Hermes Pardini (founded 1959), supported by approximately 6,000 partner laboratories and 125+ owned units. Key acquired brands include Padrão (Goiás), Diagnóstika (pathological anatomy, São Paulo), Progenética (oncology/genomics, Rio de Janeiro), DLE (genetics/rare diseases), BIOCOD (genetic counseling), Centro de Medicina Nuclear da Guanabara (Rio de Janeiro), Ecoar and Humberto Abrão (imaging/clinical analysis, Minas Gerais), Labfar and Toxicologia Pardini (toxicology), and Solução Lab (Southern Brazil). The Enterprise platform (launched 2020) provides the integrated operational backbone, connecting seven production nuclei with capacity for 160 million tests/year and real-time monitoring. The Medicina Personalizada platform aggregates genetics/genomics services across five specialized subsidiaries, offering 8,000+ test types. The group also operates digital platforms My Pardini (customer support) and Telemedicina Pardini.

Product and service25 records
1Hermes Pardini Clinical Analysis and Imaging Services
CategoryClinical Laboratory and Diagnostic Services
Description

Flagship brand of the group providing clinical analysis, diagnostic imaging, vaccines, functional tests, cryopreservation, and human/veterinary genetics through owned units in Minas Gerais and São Paulo. Also serves approximately 6,000 partner laboratories across Brazil under the Lab-to-Lab support model.

2Padrão Laboratory (Goiás)
CategoryClinical Laboratory Services
Description

Clinical analysis laboratory acquired in July 2013; the largest laboratory in Goiás state, expanding the group's analytical clinical operations and providing an important operational base in Brazil's Center-West region.

3Diagnóstika Anatomical Pathology
CategoryPathology and Cytology Services
Description

São Paulo-based anatomical pathology and molecular pathology service with over 30 years of history, specializing in surgical pathology and cytology; positioned as Brazil's largest company in pathological anatomy and molecular pathology services.

4Progenética Oncology Molecular Diagnostics
CategoryMolecular Oncology and Genomic Diagnostics
Description

Rio de Janeiro-based molecular oncology reference laboratory specializing in genomics and oncogenetics for cancer diagnostic, prognostic, and therapeutic guidance. One of the first institutions in Brazil to implement high-complexity molecular tests for personalized cancer medicine.

5Centro de Medicina Nuclear da Guanabara (CMNG)
CategoryNuclear Medicine and Diagnostic Imaging
Description

Nuclear medicine and clinical analysis provider in Rio de Janeiro state with operations in the capital, Nova Iguaçu, and Campo Grande. Operates for over 40 years with particular expertise in nuclear medicine using radioactive substances for disease diagnosis and treatment.

6Ecoar Diagnostic Imaging
CategoryDiagnostic Imaging Services
Description

Diagnostic imaging center in Belo Horizonte and metropolitan region with nearly 30 years of history, specializing in MRI, CT, echocardiography, vascular duplex scan, ultrasonography, nuclear medicine, and cardiology.

7Laboratório Humberto Abrão
CategoryPremium Clinical Analysis Services
Description

Reference laboratory for clinical analysis in Belo Horizonte with 40 years of history, serving the local medical community and premium-segment clients with high-quality services and excellence in customer care.

8Labfar Toxicology
CategoryToxicology Testing Services
Description

Toxicology laboratory specializing in drug abuse detection tests enabling wide detection windows, with INMETRO certification and DENATRAN accreditation for toxicological examinations.

9DLE Human Genetics and Rare Diseases
CategoryHuman Genetics and Rare Disease Diagnostics
Description

Reference center in human genetics and rare diseases in Brazil, specializing in molecular genetics, biochemical genetics, neonatal screening, and laboratory investigation of inborn errors of metabolism. Pioneer in implementing various genetic techniques and equipment previously unavailable in Brazil.

10BIOCOD Genetic Counseling
CategoryGenetic Counseling Services
Description

Genetic counseling and genetic testing services in human genetics and molecular biology following strict quality standards, expanding the group's molecular genetics offering.

11Toxicologia Pardini
CategoryOccupational Toxicology Testing
Description

Wide-detection toxicology services with collection units in nearly 1,000 municipalities and a base of more than 10,000 corporate clients with scientific, market, and social relevance.

12Laboratório Solução
CategoryLab-to-Lab Support Services
Description

Lab-to-Lab support services primarily in Brazil's Southern region, generating operational synergies and improving service quality and delivery times for clients in Santa Catarina and surrounding areas.

13Enterprise Integrated Diagnostic Medicine Platform
CategoryIntegrated Diagnostic Operations Platform
Description

An Integrated Intelligence Model in Diagnostic Medicine combining state-of-the-art automated equipment, a logistics network reaching 2,000+ municipalities daily, a real-time command center for production monitoring, and digital customer experience tools. Connects a central nucleus near Belo Horizonte International Airport to six advanced nuclei (São Paulo, Rio de Janeiro, Goiânia, Itajaí, and Belo Horizonte). Capacity: up to 160 million tests per year.

14Núcleo Técnico Operacional (NTO)
CategoryLaboratory Production Infrastructure
Description

Technical-Operational Center in Vespasiano (MG) featuring a horizontalized production concept with multiple automated and semi-automated lines operating in parallel with dedicated areas for specialized tests. Connected to the Central Sample Distribution (CDA) for expedited processing from receipt to result release. Capable of performing more than 5 million tests per month.

15Guardian Infectious Disease Automation
CategoryMolecular Biology Infectious Disease Testing
Description

An automated production technology model for molecular biology-based detection of infectious diseases. Operates as Brazil's largest COVID-19 testing center with full traceability and safety, prepared for 20,000 RT-PCR tests per day.

16Medicina Personalizada (Personalized Medicine Platform)
CategoryPersonalized Medicine and Genetic Diagnostics
Description

A personalized medicine platform leveraging genetics and genomics across oncology, cardiology, neurology, endocrinology, hematology, reproduction, neonatal screening, pharmacogenetics, and medical genetics. Built on five specialized companies (Progenética, Diagnóstika, DLE, BIOCOD, and Hermes Pardini's genetics division). Offers 8,000+ test types.

17Painel de Câncer Hereditário com Análise de CNVs (Hereditary Cancer Panel with CNV Analysis)
CategoryGenetic Cancer Diagnostic Test
Description

Hereditary cancer genetic test using NGS with copy number variation (CNV) analysis across multiple cancer predisposition genes in a single technique, enabling faster, more precise diagnosis for patients and families at risk for hereditary cancer syndromes.

18Painel de Câncer de Próstata HRR (CP-HRR)
CategoryOncology Molecular Diagnostic Test
Description

NGS-based prostate cancer HRR panel testing for somatic and potentially germline variants in HRR pathway genes from tumor samples, used to identify metastatic prostate cancer patients eligible for PARP inhibitor targeted therapy via the synthetic lethality mechanism.

19Teste de Deficiência do Reparo por Recombinação Homóloga (HRD)
CategoryOncology Companion Diagnostic Test
Description

HRD (Homologous Recombination Deficiency) test using the AmoyDx HRD Focus Panel kit to extract tumor DNA, investigate pathogenic variants in BRCA1 and BRCA2, and analyze 24,000 genome-wide SNPs for genomic scar scoring, used to identify ovarian cancer patients eligible for PARP inhibitor therapy.

20Teste de Triagem Neonatal Nova Era (New Era Neonatal Screening)
CategoryNewborn Genetic and Biochemical Screening
Description

Neonatal screening test combining NGS genetic analysis with LC-MS/MS mass spectrometry and conventional biochemical methods to screen for 300+ potentially treatable diseases. Differentiators include reduced false positives, rapid results within 10 business days when clinically significant biochemical alterations are found, and personalized laudos with scientific advisory support.

21Painel para Câncer de Mama e Ovário Hereditário (Hereditary Breast and Ovarian Cancer Panel)
CategoryHereditary Cancer Genetic Test
Description

Hereditary breast and ovarian cancer genetic panel analyzing multiple cancer predisposition genes beyond BRCA1/BRCA2 simultaneously via NGS, including CNV analysis. Benefits include patient/family risk identification, genetic counseling, intensive screening for early diagnosis, prophylactic surgery guidance, and targeted therapy eligibility determination.

22Imuno-histoquímica de PD-L1 (PD-L1 Immunohistochemistry)
CategoryCompanion Diagnostic Immunohistochemistry
Description

PD-L1 immunohistochemistry assay using anti-PD-L1 clone SP142 on FFPE tumor tissue read under VENTANA BenchMark ULTRA, qualitatively assessing PD-L1 protein expression in tumor-infiltrating immune cells to identify metastatic triple-negative breast cancer patients eligible for anti-PD-1 immunotherapy.

23Telemedicina Pardini
CategoryTelemedicine Services
Description

Telemedicine service platform enabling remote medical consultations and diagnostic services for patients across Brazil, accessible through a dedicated web platform.

24My Pardini Customer Support Platform
CategoryDigital Customer Engagement Platform
Description

Digital support platform providing customer relationship management and administrative services for the group's client support operations, available as both a web platform and mobile application.

25Lab-to-Lab (L2L) B2B Laboratory Support Services
CategoryB2B Laboratory Support Services
Description

B2B laboratory support services serving approximately 6,000 partner laboratories across Brazil with specialized testing, quality assessments, and operational support. Enables smaller laboratories to extend their test menus and access high-complexity diagnostics without capital investment.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fleury is one of Brazil's largest diagnostic medicine groups, with a strong presence in São Paulo and Rio de Janeiro. Competes directly with Pardini in clinical analysis, diagnostic imaging, genetics, and personalized medicine, with a similar multi-channel revenue model.

TypeBroad incumbent
Description

Sonic Healthcare is a global medical diagnostics operator with pathology and laboratory services across Australia, Europe, and North America. As a broad incumbent it does not compete in Brazil, but serves as a comparable peer for international roll-up strategies and lab automation at scale.

TypeBroad incumbent
Description

Unilabs is a European leader in clinical diagnostics and specialized laboratory testing, operating across multiple geographies with a focus on hub-and-spoke operations. As a broad incumbent it does not directly compete in Brazil, but provides a relevant benchmark for European-style diagnostics consolidation and operational centralization.

4Sabin Diagnóstico e Saúde
TypeDirect peer
Description

Sabin is a major Brazilian diagnostic medicine group with national expansion, offering clinical analysis, imaging, and specialized testing. Competes directly with Pardini in mid-tier cities and serves similar insurance and corporate customer segments.

TypeEmerging player
Description

Hilab is a Brazilian digital diagnostics startup offering connected point-of-care testing with cloud-based result delivery. Represents an emerging direct competitor in decentralized testing, particularly in occupational health and primary care, where Pardini's Lab-to-Lab model also operates.

TypeBroad incumbent
Description

Labcorp is a global leader in clinical laboratory services and diagnostics with a broad portfolio spanning routine, esoteric, and genetic testing. As a broad incumbent it does not directly compete in Brazil, but its centralized lab production and personalized medicine strategy parallels Pardini's Enterprise platform thesis.

TypeBroad incumbent
Description

Synlab is Europe's largest medical diagnostics services provider, operating centralized laboratory hubs across multiple countries. As a broad incumbent it does not directly compete in Brazil, but its hub-and-spoke centralized production model closely mirrors Pardini's Enterprise platform architecture.

TypeRegional player
Description

BPL Medical is a regional diagnostic laboratory group with strong presence in Minas Gerais and parts of the Southeast, directly overlapping with Pardini's strongest geography. It competes for the same partner labs, hospitals, and patient volumes in BH and surrounding regions.

TypeBroad incumbent
Description

Quest Diagnostics is one of the world's largest clinical laboratory services companies, offering routine and advanced diagnostics including genetics. As a broad incumbent it does not directly compete in Brazil, but provides a global benchmark for lab automation, lab-to-lab B2B models, and personalized medicine scale that informs Pardini's strategic trajectory.

TypeDirect peer
Description

Dasa is Brazil's largest diagnostic medicine company, offering clinical analysis, imaging, and molecular diagnostics through a national network of owned units and partner labs. It is the closest direct competitor to Pardini in scale, business model (B2B + B2C + insurance billing), and Brazilian footprint.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pardini Group

Diagnostic Medicine and Clinical Laboratory Servicesgrupopardini.com.br

Grupo Pardini is a publicly listed Brazilian diagnostic medicine company serving patients, 6,000+ partner laboratories, health insurers, and 10,000+ corporate clients across 1,930+ municipalities through 125 owned units and an integrated platform spanning clinical analysis, genomics, imaging, and toxicology.

What Pardini Group does

Pardini Group (legal name Grupo Hermes Pardini, public ticker PARDINI on B3 Novo Mercado) is a Brazilian diagnostic medicine company founded in 1959 by Dr. Hermes Pardini in Belo Horizonte, Minas Gerais, now headquartered in Vespasiano. The group operates an integrated diagnostic platform combining 125 owned service units, approximately 6,000 partner laboratories served via the Lab-to-Lab B2B channel, and coverage reaching 1,930-2,000+ Brazilian municipalities. It offers more than 8,000 test types spanning clinical analysis, diagnostic imaging, vaccination, cryopreservation, human and veterinary genetics, toxicology, oncology genomics, and personalized medicine, organized across 14 brands including Hermes Pardini (flagship), Padrão, Diagnostika, Progenetica, CMNG, Ecoar, Humberto Abrão, Labfar, DLE, Biocod, Toxicologia Pardini, Solução, My Pardini, and Telemedicina Pardini.

The underlying technology stack is anchored by the Vespasiano-based Núcleo Técnico Operacional (NTO), described as the world's largest specialized laboratory production hub by installed capacity and capable of processing more than 5 million tests per month via parallel automated and semi-automated lines. The 2020-launched Enterprise platform extends this to seven interconnected production nuclei (central nucleus near Belo Horizonte International Airport plus six advanced nuclei) with combined capacity for 160 million tests annually, real-time command center monitoring, and a Just-in-Time reagent model replacing direct procurement. Advanced diagnostic modalities include Next-Generation Sequencing with CNV analysis for hereditary cancer panels and HRD/HRR panels, LC-MS/MS mass spectrometry enabling newborn screening for over 300 treatable diseases, PD-L1 immunohistochemistry on VENTANA BenchMark ULTRA, and the Guardian automated molecular biology platform operating Brazil's largest COVID-19 RT-PCR testing center at 20,000 tests per day. R$200 million+ has been invested in technology infrastructure.

The business model operates four parallel revenue streams: (1) direct patient services at owned units billed primarily through health insurance operators on a transactional fee basis, (2) Lab-to-Lab B2B professional services and specialized testing to approximately 6,000 partner laboratories, (3) enterprise billing to health insurance operators and self-management plans via a dedicated commercial team, and (4) specialized professional services in toxicology (10,000+ corporate clients) and personalized medicine (600+ physicians, 3 million+ tests performed last year). The Pardini family retains 64.7% ownership post-IPO; the company has executed more than 12 acquisitions between 2012-2019 to build geographic and specialty breadth, and pursues an explicit strategy of democratizing access to advanced diagnostics across urban and rural Brazil through the Enterprise logistics network.

Pardini Group firmographics

Firmographics
Name
Pardini Group
Legal name
Grupo Hermes Pardini
Website
https://grupopardini.com.br
Company type
Public
Founded year
1959
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Grupo Pardini is a publicly listed Brazilian diagnostic medicine company serving patients, 6,000+ partner laboratories, health insurers, and 10,000+ corporate clients across 1,930+ municipalities through 125 owned units and an integrated platform spanning clinical analysis, genomics, imaging, and toxicology.
Ownership category
akta.pro rank

Where Pardini Group is headquartered

Location

Headquarters

HQ city
Vespasiano
HQ country
Brazil
HQ region
Latin America

Offices15 records

Markets served

Pardini Group business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Laboratory Diagnostic Services: Clinical analysis, diagnostic imaging, vaccination, cryopreservation, and genetic testing services provided to patients at owned units and through health insurance billing.
  2. Laboratory Support Services (Lab-to-Lab): B2B services provided to approximately 6,000 partner laboratories across Brazil, including specialized testing, assessments, and operational support.
  3. Health Insurance Operator Services: Services billed through health insurance operators, self-management companies, and health insurance providers.
  4. Specialized Testing Services: Toxicology testing, personalized medicine, genetic testing, and other specialized diagnostic services.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Pardini Group product offering

Product offering

Core offering

Grupo Pardini is a Brazilian diagnostic medicine group that provides clinical analysis, diagnostic imaging, vaccination, cryopreservation, genetic and genomic testing, toxicology, and personalized medicine services through 125 owned service units and a lab-to-lab B2B support network reaching approximately 6,000 partner laboratories across 1,930 municipalities. The group operates one of the largest automated laboratory production hubs in the world, capable of processing more than 5 million tests per month and up to 160 million tests per year through its Enterprise integrated model.

Product overview

Pardini Group is a Brazilian diagnostic medicine company organized as a multi-brand portfolio spanning clinical analysis, diagnostic imaging, genetics, toxicology, telemedicine, and personalized medicine. The core platform is Hermes Pardini (founded 1959), supported by approximately 6,000 partner laboratories and 125+ owned units. Key acquired brands include Padrão (Goiás), Diagnóstika (pathological anatomy, São Paulo), Progenética (oncology/genomics, Rio de Janeiro), DLE (genetics/rare diseases), BIOCOD (genetic counseling), Centro de Medicina Nuclear da Guanabara (Rio de Janeiro), Ecoar and Humberto Abrão (imaging/clinical analysis, Minas Gerais), Labfar and Toxicologia Pardini (toxicology), and Solução Lab (Southern Brazil). The Enterprise platform (launched 2020) provides the integrated operational backbone, connecting seven production nuclei with capacity for 160 million tests/year and real-time monitoring. The Medicina Personalizada platform aggregates genetics/genomics services across five specialized subsidiaries, offering 8,000+ test types. The group also operates digital platforms My Pardini (customer support) and Telemedicina Pardini.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hermes Pardini Clinical Analysis and Imaging Services Flagship brand of the group providing clinical analysis, diagnostic imaging, vaccines, functional tests, cryopreservation, and human/veterinary genetics through owned units in Minas Gerais and São Paulo. Also serves approximately 6,000 partner laboratories across Brazil under the Lab-to-Lab support model.
  • Padrão Laboratory (Goiás) Clinical analysis laboratory acquired in July 2013; the largest laboratory in Goiás state, expanding the group's analytical clinical operations and providing an important operational base in Brazil's Center-West region.
  • Diagnóstika Anatomical Pathology São Paulo-based anatomical pathology and molecular pathology service with over 30 years of history, specializing in surgical pathology and cytology; positioned as Brazil's largest company in pathological anatomy and molecular pathology services.
  • Progenética Oncology Molecular Diagnostics Rio de Janeiro-based molecular oncology reference laboratory specializing in genomics and oncogenetics for cancer diagnostic, prognostic, and therapeutic guidance. One of the first institutions in Brazil to implement high-complexity molecular tests for personalized cancer medicine.
  • Centro de Medicina Nuclear da Guanabara (CMNG) Nuclear medicine and clinical analysis provider in Rio de Janeiro state with operations in the capital, Nova Iguaçu, and Campo Grande. Operates for over 40 years with particular expertise in nuclear medicine using radioactive substances for disease diagnosis and treatment.
  • Ecoar Diagnostic Imaging Diagnostic imaging center in Belo Horizonte and metropolitan region with nearly 30 years of history, specializing in MRI, CT, echocardiography, vascular duplex scan, ultrasonography, nuclear medicine, and cardiology.
  • Laboratório Humberto Abrão Reference laboratory for clinical analysis in Belo Horizonte with 40 years of history, serving the local medical community and premium-segment clients with high-quality services and excellence in customer care.
  • Labfar Toxicology Toxicology laboratory specializing in drug abuse detection tests enabling wide detection windows, with INMETRO certification and DENATRAN accreditation for toxicological examinations.
  • DLE Human Genetics and Rare Diseases Reference center in human genetics and rare diseases in Brazil, specializing in molecular genetics, biochemical genetics, neonatal screening, and laboratory investigation of inborn errors of metabolism. Pioneer in implementing various genetic techniques and equipment previously unavailable in Brazil.
  • BIOCOD Genetic Counseling Genetic counseling and genetic testing services in human genetics and molecular biology following strict quality standards, expanding the group's molecular genetics offering.
  • Toxicologia Pardini Wide-detection toxicology services with collection units in nearly 1,000 municipalities and a base of more than 10,000 corporate clients with scientific, market, and social relevance.
  • Laboratório Solução Lab-to-Lab support services primarily in Brazil's Southern region, generating operational synergies and improving service quality and delivery times for clients in Santa Catarina and surrounding areas.
  • Enterprise Integrated Diagnostic Medicine Platform An Integrated Intelligence Model in Diagnostic Medicine combining state-of-the-art automated equipment, a logistics network reaching 2,000+ municipalities daily, a real-time command center for production monitoring, and digital customer experience tools. Connects a central nucleus near Belo Horizonte International Airport to six advanced nuclei (São Paulo, Rio de Janeiro, Goiânia, Itajaí, and Belo Horizonte). Capacity: up to 160 million tests per year.
  • Núcleo Técnico Operacional (NTO) Technical-Operational Center in Vespasiano (MG) featuring a horizontalized production concept with multiple automated and semi-automated lines operating in parallel with dedicated areas for specialized tests. Connected to the Central Sample Distribution (CDA) for expedited processing from receipt to result release. Capable of performing more than 5 million tests per month.
  • Guardian Infectious Disease Automation An automated production technology model for molecular biology-based detection of infectious diseases. Operates as Brazil's largest COVID-19 testing center with full traceability and safety, prepared for 20,000 RT-PCR tests per day.
  • Medicina Personalizada (Personalized Medicine Platform) A personalized medicine platform leveraging genetics and genomics across oncology, cardiology, neurology, endocrinology, hematology, reproduction, neonatal screening, pharmacogenetics, and medical genetics. Built on five specialized companies (Progenética, Diagnóstika, DLE, BIOCOD, and Hermes Pardini's genetics division). Offers 8,000+ test types.
  • Painel de Câncer Hereditário com Análise de CNVs (Hereditary Cancer Panel with CNV Analysis) Hereditary cancer genetic test using NGS with copy number variation (CNV) analysis across multiple cancer predisposition genes in a single technique, enabling faster, more precise diagnosis for patients and families at risk for hereditary cancer syndromes.
  • Painel de Câncer de Próstata HRR (CP-HRR) NGS-based prostate cancer HRR panel testing for somatic and potentially germline variants in HRR pathway genes from tumor samples, used to identify metastatic prostate cancer patients eligible for PARP inhibitor targeted therapy via the synthetic lethality mechanism.
  • Teste de Deficiência do Reparo por Recombinação Homóloga (HRD) HRD (Homologous Recombination Deficiency) test using the AmoyDx HRD Focus Panel kit to extract tumor DNA, investigate pathogenic variants in BRCA1 and BRCA2, and analyze 24,000 genome-wide SNPs for genomic scar scoring, used to identify ovarian cancer patients eligible for PARP inhibitor therapy.
  • Teste de Triagem Neonatal Nova Era (New Era Neonatal Screening) Neonatal screening test combining NGS genetic analysis with LC-MS/MS mass spectrometry and conventional biochemical methods to screen for 300+ potentially treatable diseases. Differentiators include reduced false positives, rapid results within 10 business days when clinically significant biochemical alterations are found, and personalized laudos with scientific advisory support.
  • Painel para Câncer de Mama e Ovário Hereditário (Hereditary Breast and Ovarian Cancer Panel) Hereditary breast and ovarian cancer genetic panel analyzing multiple cancer predisposition genes beyond BRCA1/BRCA2 simultaneously via NGS, including CNV analysis. Benefits include patient/family risk identification, genetic counseling, intensive screening for early diagnosis, prophylactic surgery guidance, and targeted therapy eligibility determination.
  • Imuno-histoquímica de PD-L1 (PD-L1 Immunohistochemistry) PD-L1 immunohistochemistry assay using anti-PD-L1 clone SP142 on FFPE tumor tissue read under VENTANA BenchMark ULTRA, qualitatively assessing PD-L1 protein expression in tumor-infiltrating immune cells to identify metastatic triple-negative breast cancer patients eligible for anti-PD-1 immunotherapy.
  • Telemedicina Pardini Telemedicine service platform enabling remote medical consultations and diagnostic services for patients across Brazil, accessible through a dedicated web platform.
  • My Pardini Customer Support Platform Digital support platform providing customer relationship management and administrative services for the group's client support operations, available as both a web platform and mobile application.
  • Lab-to-Lab (L2L) B2B Laboratory Support Services B2B laboratory support services serving approximately 6,000 partner laboratories across Brazil with specialized testing, quality assessments, and operational support. Enables smaller laboratories to extend their test menus and access high-complexity diagnostics without capital investment.

Quantifiable outcome

  • 160 million tests per year capacity across seven production nuclei
  • +5 more outcomes

Companies that use Pardini Group

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Pardini Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Pardini Group partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Pardini Group competitors and assessment

Company assessment

Direct peers

  • Grupo Fleury: Fleury is one of Brazil's largest diagnostic medicine groups, with a strong presence in São Paulo and Rio de Janeiro. Competes directly with Pardini in clinical analysis, diagnostic imaging, genetics, and personalized medicine, with a similar multi-channel revenue model.
  • Sabin Diagnóstico e Saúde: Sabin is a major Brazilian diagnostic medicine group with national expansion, offering clinical analysis, imaging, and specialized testing. Competes directly with Pardini in mid-tier cities and serves similar insurance and corporate customer segments.
  • Dasa (Diagnósticos da América): Dasa is Brazil's largest diagnostic medicine company, offering clinical analysis, imaging, and molecular diagnostics through a national network of owned units and partner labs. It is the closest direct competitor to Pardini in scale, business model (B2B + B2C + insurance billing), and Brazilian footprint.

Broad incumbents

  • Sonic Healthcare: Sonic Healthcare is a global medical diagnostics operator with pathology and laboratory services across Australia, Europe, and North America. As a broad incumbent it does not compete in Brazil, but serves as a comparable peer for international roll-up strategies and lab automation at scale.
  • Unilabs: Unilabs is a European leader in clinical diagnostics and specialized laboratory testing, operating across multiple geographies with a focus on hub-and-spoke operations. As a broad incumbent it does not directly compete in Brazil, but provides a relevant benchmark for European-style diagnostics consolidation and operational centralization.
  • Laboratory Corporation of America (Labcorp): Labcorp is a global leader in clinical laboratory services and diagnostics with a broad portfolio spanning routine, esoteric, and genetic testing. As a broad incumbent it does not directly compete in Brazil, but its centralized lab production and personalized medicine strategy parallels Pardini's Enterprise platform thesis.
  • Synlab: Synlab is Europe's largest medical diagnostics services provider, operating centralized laboratory hubs across multiple countries. As a broad incumbent it does not directly compete in Brazil, but its hub-and-spoke centralized production model closely mirrors Pardini's Enterprise platform architecture.
  • Quest Diagnostics: Quest Diagnostics is one of the world's largest clinical laboratory services companies, offering routine and advanced diagnostics including genetics. As a broad incumbent it does not directly compete in Brazil, but provides a global benchmark for lab automation, lab-to-lab B2B models, and personalized medicine scale that informs Pardini's strategic trajectory.

Emerging players

  • Hilab: Hilab is a Brazilian digital diagnostics startup offering connected point-of-care testing with cloud-based result delivery. Represents an emerging direct competitor in decentralized testing, particularly in occupational health and primary care, where Pardini's Lab-to-Lab model also operates.

Regional players

  • BPL Medical (Belo Horizonte Patologia e Laboratórios): BPL Medical is a regional diagnostic laboratory group with strong presence in Minas Gerais and parts of the Southeast, directly overlapping with Pardini's strongest geography. It competes for the same partner labs, hospitals, and patient volumes in BH and surrounding regions.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Pardini Group social profiles

Digital presence

Pardini Group compliance and trust

Trust signal

Compliance3 records

Pardini Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pardini Group leadership team

Management profile

Number of profiles

Profiles10 records

Pardini Group subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Pardini Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pardini Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pardini Group

What does Pardini Group do?

Grupo Pardini is a Brazilian diagnostic medicine group that provides clinical analysis, diagnostic imaging, vaccination, cryopreservation, genetic and genomic testing, toxicology, and personalized medicine services through 125 owned service units and a lab-to-lab B2B support network reaching approximately 6,000 partner laboratories across 1,930 municipalities. The group operates one of the largest automated laboratory production hubs in the world, capable of processing more than 5 million tests per month and up to 160 million tests per year through its Enterprise integrated model.

Is Pardini Group a public or private company?

Pardini Group is a public company. It is classified as public and is currently operating.

When was Pardini Group founded?

Pardini Group was founded in 1959. It employs 1,001 to 5,000 people.

Where is Pardini Group based?

Pardini Group is headquartered in Vespasiano, Brazil, in the Latin America region.

How does Pardini Group make money?

Four revenue lines are on record. Laboratory Diagnostic Services are the primary driver. The others are laboratory Support Services (Lab-to-Lab), health Insurance Operator Services and specialized Testing Services.

Who are Pardini Group's main competitors?

Direct peers on record are Grupo Fleury, Sabin Diagnóstico e Saúde and Dasa (Diagnósticos da América). Broad incumbents are Sonic Healthcare, Unilabs, Laboratory Corporation of America (Labcorp), Synlab and Quest Diagnostics. Hilab is listed as an emerging player. BPL Medical (Belo Horizonte Patologia e Laboratórios) is listed as a regional player.

Does Pardini Group have an API?

No public API is recorded for Pardini Group.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals